Aclarion Expands CLARITY Trial to University of Arizona, Boosting Spine Surgery Research — Aclarion, Inc.

Event summary

University of Arizona College of Medicine – Phoenix joins Aclarion's CLARITY trial as the 10th site, adding expertise in complex spine surgery and clinical research.
CLARITY trial now includes 10 high-volume sites, including Johns Hopkins University and Northwestern Medicine.
Trial aims to enroll 300 patients, with initial internal data readout and interim results expected in Q4 2026.
Nociscan's success rate is 97% when all Nociscan-positive discs are treated.
Chronic low back pain affects approximately 266 million people worldwide.

The big picture

Aclarion's expansion of the CLARITY trial to the University of Arizona College of Medicine – Phoenix underscores the growing interest in integrating Nociscan into spine surgery workflows. The trial's success could position Nociscan as a standard of care for identifying sources of chronic low back pain, addressing a significant unmet need in the healthcare market. The inclusion of top-tier medical institutions highlights the strategic importance of the trial in validating Nociscan's clinical and economic value.

What we're watching

Trial Momentum: The pace at which Aclarion can enroll patients and generate interim data will determine Nociscan's path to regulatory approval and market adoption.
Clinical Validation: Whether the CLARITY trial can demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain will be critical for its adoption.
Market Expansion: How Aclarion leverages the trial results to expand Nociscan's use in real-world clinical workflows will impact its long-term success.